Clarissa Koch | Chief Scientific Officer
Leyden Labs

Clarissa Koch is Chief Scientific Officer at Leyden Labs, where she leads the scientific strategy and research behind antibody-based nasal sprays designed to prevent infection from respiratory viruses. Their work focuses on scalable, non-invasive prophylactic platforms that offer broad protection against both current and emerging respiratory viral threats. Clarissa’s scientific background spans respiratory virology, precision oncology, and cardiac amyloidosis. She completed her Ph.D. at Boston University, and postdoctoral work in the Division of Pulmonary and Critical Care at Northwestern University centered on respiratory viral pathogens, including influenza, RSV, and SARS-CoV-2. She previously worked on precision oncology approaches for breast cancer at Agendia.